References
1.Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999;340:115–126.
2.Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995;91:2844–2850.
3.Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;36:973–979.
4.Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–843.
5.Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;101:1767–1772.
6.Harris TB, Ferrucci L, Tracy RP, et al. Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999;106:506–512.
7.Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149–2153.
8.Ernst E, and Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993;118:956–963.
9.Ridker PM. Evaluating novel cardiovascular risk factors: can we better predict heart attack? Ann Intern Med 1999;130:933–937.
10.Pearson TA, Mensah GA, Alexander RW, et al. Centers for Disease Control and Prevention, American Heart Association. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for heathcare professionals from the centers for disease control and prevention and the American Heart Asssociation. Circulation 2003;107:499–511.
11.De Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes.Circulation 2003;107:690–695.
12.Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol2000;20:2094–2099.
13.Bhakdi S, Torzewski M, Klouche M, et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol1999;19:2348–2354.
14.Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194–1197.
15.Ford ES. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care1999;22:1971–1977.
16.Kannel WB, D’Agostino RB, Wilson PW, et al. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990;120:672–676.
17.Streja D, Cressey P, Rabkin SW. Associations between inflammatory markers, traditional risk factors, and complications in patients with type 2 diabetes mellitus. J Diabetes Complicat 2003;17:120–127.
18.Pignoli P, Tremoli E, Poli A, et al. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986;74:1399–1406.
19.O’Leary DH, Polak JF, Kronmal RA, et al. Distribution and correlate of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group.Stroke 1992;23:1752–1760.
20.Crouse JR III, Craven TE, Hageman AP, et al. Association of coronary disease with segment-specific intimal-medial thicking of the extracranical carotid artery. Circulation 1995;92:1141–1147.
21.Davis MD. Natural evolution. In: Current Diagnosis and Management of Chorioretinal Diseases (ed by L’Esperance FA Jr), p 179–184, CV Mosby, St Louis, 1974.
22.Handa N, Matsumoto M, Maeda H, et al. Ultrasonic evaluation of carotid atherosclerosis. Stroke1990;30:1567–1572.
23.Takebayashi K, Aso Y, Matsutomo R, et al. The association between the corrected QT intervals and combined intimal-medial thickness of the carotid artery in patients with type 2 diabetes. Metabolism2004;53:1152–1157.
24.Cook DG, Mendall MA, Whincup PH, et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000;149:139–150.
25.Mendall MA, Strachan DP, Butland BK, et al. C-reactive protein: relation to total mortality, cardiovascular risk factors in men. Eur Heart J 2000;21:1584–1590.
26.Winbeck K, Kukla C, Poppert H, et al. Elevated C-reactive protein is associated with an increased intima media thickness of the common carotid artery. Cardiovasc Dis 2002;13:57–63.
27.Bielak LF, Klee CG, Sheedy, II PF, et al. Association of fibrinogen with quantity of coronary artery calcification measured by electron beam computed tomography. Arterioscler Thromb Vasc Biol2000;20:2167–2171.
28.Festa A, D’Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome. The insulin resistance atherosclerosis study (IRAS). Circulation 2002;102:42–47.
29.Bruno G, Cavallo-Perin P, Bargero G, et al. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Ann Intern Med1996;125:653–657.